A Phase II Study of Gemcitabine and Erlotinib As Adjuvant Therapy In Patients With Resected Pancreatic Cancer

PHASE2TerminatedINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

June 30, 2006

Primary Completion Date

October 31, 2011

Study Completion Date

November 30, 2011

Conditions
Pancreatic Cancer
Interventions
DRUG

Gemcitabine

1500mg/m2 IV over 150 min IV q 2 weeks 4 months

DRUG

Erlotinib

150 mg/d Daily, oral 12 months

Trial Locations (1)

15232

UPMC Cancer Centers Network, Pittsburgh

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Genentech, Inc.

INDUSTRY

lead

Herbert J. Zeh, III MD, FACS

OTHER